Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 501

1.

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul 30. doi: 10.1038/s41416-019-0534-2. [Epub ahead of print]

PMID:
31363170
2.

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG.

Clin Gastroenterol Hepatol. 2019 Jul 12. pii: S1542-3565(19)30743-8. doi: 10.1016/j.cgh.2019.07.010. [Epub ahead of print]

PMID:
31306800
3.

Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation.

Kim CG, Lee HW, Choi HJ, Lee JI, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK.

Cancer Med. 2019 Jul 10. doi: 10.1002/cam4.2417. [Epub ahead of print]

4.

Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma.

Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J.

Strahlenther Onkol. 2019 Jul 8. doi: 10.1007/s00066-019-01488-9. [Epub ahead of print]

PMID:
31286149
5.

Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases.

Kim KH, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU.

Eur J Gastroenterol Hepatol. 2019 Jul 5. doi: 10.1097/MEG.0000000000001475. [Epub ahead of print]

PMID:
31283527
6.

Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.

Up Kim S, Seo YS, Lee HA, Kim MN, Kim EH, Kim HY, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY.

Clin Gastroenterol Hepatol. 2019 Jun 25. pii: S1542-3565(19)30666-4. doi: 10.1016/j.cgh.2019.06.028. [Epub ahead of print]

PMID:
31252188
7.

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW.

Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum in: Br J Cancer. 2019 Jul 30;:.

PMID:
31249394
8.

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection.

Kim HS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Park YN, Han DH, Kim KS, Choi JS, Choi GH, Kim HS.

Clin Mol Hepatol. 2019 Jun 27. doi: 10.3350/cmh.2018.0073. [Epub ahead of print]

9.

Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.

Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han KH, Choi JY, Kim DY.

J Vasc Interv Radiol. 2019 Aug;30(8):1194-1200.e1. doi: 10.1016/j.jvir.2019.03.016. Epub 2019 Jun 22.

PMID:
31235408
10.

Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.

Kim DS, Lim TS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baatarkhuu O, Kim SU.

Dig Dis Sci. 2019 Jun 11. doi: 10.1007/s10620-019-05701-8. [Epub ahead of print]

PMID:
31187326
11.

Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea.

Lee HS, Choi GH, Choi JS, Han KH, Ahn SH, Kim DY, Park JY, Kim SU, Kim SH, Yoon DS, Kim JK, Choi JW, Kim SS, Park H.

Ann Surg Treat Res. 2019 Jun;96(6):275-282. doi: 10.4174/astr.2019.96.6.275. Epub 2019 May 29.

12.

Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B.

Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU.

Clin Mol Hepatol. 2019 May 31. doi: 10.3350/cmh.2018.0103. [Epub ahead of print]

13.

Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.

Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK.

Clin Transl Gastroenterol. 2019 Jun;10(6):e00036. doi: 10.14309/ctg.0000000000000036.

14.

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea.

Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, Han KH, Kim DY.

Clin Mol Hepatol. 2019 May 20. doi: 10.3350/cmh.2018.0065. [Epub ahead of print]

15.

Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.

König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP.

J Hepatol. 2019 Aug;71(2):289-300. doi: 10.1016/j.jhep.2019.04.010. Epub 2019 May 8.

16.

External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.

Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK.

Liver Int. 2019 May 3. doi: 10.1111/liv.14129. [Epub ahead of print]

PMID:
31050379
17.

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.

Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yeon JE, Byun KS, Kim HS, Kim JH, Kim SU.

BMC Cancer. 2019 Apr 16;19(1):363. doi: 10.1186/s12885-019-5495-6.

18.

Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Chon YE, Park H, Hyun HK, Ha Y, Kim MN, Kim BK, Lee JH, Kim SU, Kim DY, Ahn SH, Hwang SG, Han KH, Rim KS, Park JY.

Cancers (Basel). 2019 Apr 10;11(4). pii: E509. doi: 10.3390/cancers11040509.

19.

A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.

Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY.

J Hepatol. 2019 Sep;71(3):456-464. doi: 10.1016/j.jhep.2019.03.028. Epub 2019 Apr 6.

PMID:
30959156
20.

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.

Jeon MY, Kim HS, Lim TS, Han DH, Kim BK, Park JY, Kim DY, Ahn SH, Choi GH, Choi JS, Han KH, Kim SU.

PLoS One. 2019 Apr 4;14(4):e0214613. doi: 10.1371/journal.pone.0214613. eCollection 2019.

Supplemental Content

Loading ...
Support Center